As several epidemiological studies associate circulating HDL levels with reduced AD risk (Zuliani et al., 2010), and we recently demonstrated that a single intravenous injection of reconstituted HDL (rHDL) acutely lowers soluble brain Aβ levels in APP/PS1 mice (Robert et al., 2016), we reasoned that circulating HDL might promote Aβ recovery into the circulation and reduce its accumulation in bioengineered vessels. Here, APP is linked to Alzheimer disease.